 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546 |
- lopinavir/ritonavir / Generic mfg.
New P4 trial, Monotherapy: Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily (clinicaltrials.gov) - Apr 18, 2012
P4, N=30, Recruiting, Sponsor: Daniel Podzamczer
- | Isentress (raltegravir) / Merck (MSD)
New P4 trial: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (clinicaltrials.gov) - Apr 10, 2012
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
- lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion: Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir (clinicaltrials.gov) - Apr 10, 2012
P4, N=50, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed
- Enrollment change, Combination therapy: Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV (clinicaltrials.gov) - Apr 8, 2012
P2, N=16, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=50 --> 16
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin (clinicaltrials.gov) - Apr 3, 2012
P1, N=52, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Invirase (saquinavir) / Roche
Enrollment change: Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV (clinicaltrials.gov) - Apr 2, 2012
P1/2, N=26, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=50 --> 16 N=48 --> 26
- tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Enrollment change: Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (clinicaltrials.gov) - Apr 2, 2012
P2, N=53, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=48 --> 26 N=108 --> 53
- Invirase (saquinavir) / Roche
Trial completion: Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV (clinicaltrials.gov) - Apr 2, 2012
P1/2, N=26, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=108 --> 53 Active, not recruiting --> Completed
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=16, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed N=36 --> 16
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=16, Completed, Sponsor: University of Colorado, Denver
N=36 --> 16 Recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment closed: AP6142: Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) (clinicaltrials.gov) - Mar 27, 2012
P1, N=24, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults (clinicaltrials.gov) - Mar 19, 2012
P=N/A, N=2, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=204 --> 2
- gemfibrozil / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: GEM-PK: Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=15, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=204 --> 2 N=30 --> 15
- lopinavir/ritonavir / Generic mfg.
Trial initiation date: RELATES: Relationship Between HIV-1 Subtype and ARV Response (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=108, Completed, Sponsor: University of Wisconsin, Madison
N=30 --> 15 Initiation date: Feb 2007 --> Jul 2008
- lopinavir/ritonavir / Generic mfg.
Enrollment change: RELATES: Relationship Between HIV-1 Subtype and ARV Response (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=108, Completed, Sponsor: University of Wisconsin, Madison
Initiation date: Feb 2007 --> Jul 2008 N=300 --> 108
- lopinavir/ritonavir / Generic mfg.
Trial completion: RELATES: Relationship Between HIV-1 Subtype and ARV Response (clinicaltrials.gov) - Mar 8, 2012
P=N/A, N=108, Completed, Sponsor: University of Wisconsin, Madison
N=300 --> 108 Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial initiation date, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Mar 7, 2012
P2, N=40, Recruiting, Sponsor: McGill University Health Center
Recruiting --> Completed Initiation date: Dec 2010 --> Dec 2011
- Isentress (raltegravir) / Merck (MSD)
Enrollment open, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Mar 7, 2012
P2, N=40, Recruiting, Sponsor: McGill University Health Center
Initiation date: Dec 2010 --> Dec 2011 Not yet recruiting --> Recruiting
- | abacavir/lamivudine/zidovudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, Monotherapy: KALIPO: Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC (clinicaltrials.gov) - Feb 28, 2012
P4, N=38, Completed, Sponsor: Fundacion SEIMC-GESIDA
Not yet recruiting --> Recruiting N=112 --> 38
- || efavirenz / Generic mfg., lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: LYNX: A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine (clinicaltrials.gov) - Feb 22, 2012
P=N/A, N=346, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=112 --> 38 N=510 --> 346
- || lopinavir/ritonavir / Generic mfg.
Enrollment change: QD-Kapital: Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) (clinicaltrials.gov) - Feb 19, 2012
P=N/A, N=97, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=510 --> 346 N=300 --> 97
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: QD-Kapital: Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) (clinicaltrials.gov) - Feb 19, 2012
P=N/A, N=97, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=300 --> 97 Recruiting --> Completed
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial withdrawal: Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (clinicaltrials.gov) - Feb 13, 2012
P3, N=0, Withdrawn, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Completed Suspended --> Withdrawn
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (clinicaltrials.gov) - Feb 13, 2012
P3, N=0, Withdrawn, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Suspended --> Withdrawn N=960 --> 0
- | Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (clinicaltrials.gov) - Feb 13, 2012
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
- | Trial completion: Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) (clinicaltrials.gov) - Feb 13, 2012
P3, N=120, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=960 --> 0 Active, not recruiting --> Completed
- tenofovir disoproxil fumarate / Generic mfg., didanosine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Journal, Metastases: Study of Anti-HIV Therapy Intensification (clinicaltrials.gov) - Feb 12, 2012
P=N/A, N=22, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: ARKS: Anti-Retrovirals for Kaposi's Sarcoma (clinicaltrials.gov) - Feb 8, 2012
P4, N=224, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Withdrawn --> Active, not recruiting
- | Isentress (raltegravir) / Merck (MSD)
Enrollment open: RASSTER: RAltegravir Switch STudy: Effects on Endothelial Recovery (clinicaltrials.gov) - Feb 5, 2012
P4, N=24, Recruiting, Sponsor: UMC Utrecht
Withdrawn --> Active, not recruiting Not yet recruiting --> Recruiting
- fenofibric acid / Generic mfg.
Enrollment change, Combination therapy: The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Feb 2, 2012
P1, N=25, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting N=50 --> 25
- fenofibric acid / Generic mfg.
Trial completion, Combination therapy: The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Feb 2, 2012
P1, N=25, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=50 --> 25 Recruiting --> Completed
- || lopinavir/ritonavir / Generic mfg.
Enrollment change: Drug Use Investigation of Kaletra (clinicaltrials.gov) - Jan 30, 2012
P=N/A, N=1184, Completed, Sponsor: Abbott
Recruiting --> Completed N=3887 --> 1184
- |||||||||| darunavir/ritonavir / Generic mfg.
New P3 trial: Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (clinicaltrials.gov) - Jan 23, 2012
P3, N=316, Completed, Sponsor: Janssen-Cilag G.m.b.H
- zidovudine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=529, Completed, Sponsor: AIDS Clinical Trials Group
N=3887 --> 1184 N=372 --> 529
- | Isentress (raltegravir) / Merck (MSD)
New P4 trial: Bone and Body Comp: A Sub Study of the SECOND-LINE Study (clinicaltrials.gov) - Jan 18, 2012
P4, N=211, Completed, Sponsor: Kirby Institute
- nevirapine / Generic mfg.
Trial completion: Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (clinicaltrials.gov) - Jan 17, 2012
P2, N=484, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=372 --> 529 Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment closed: SPARE: Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (clinicaltrials.gov) - Jan 16, 2012
P=N/A, N=54, Active, not recruiting, Sponsor: National Center for Global Health and Medicine, Japan
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| Selzentry (maraviroc) / ViiV Healthcare
New P4 trial, Combination therapy: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra (EUDRACT) - Jan 3, 2012
P4, N=280, Ongoing, Sponsor: Camden Provider Services
- || lopinavir/ritonavir / Generic mfg.
Enrollment change: EOLE: Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=94, Completed, Sponsor: Abbott
Enrolling by invitation --> Active, not recruiting N=200 --> 94
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: EOLE: Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=94, Completed, Sponsor: Abbott
N=200 --> 94 Active, not recruiting --> Completed
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: Kaletra: Therapy With Double Protease Inhibitors (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=65, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Completed
- | emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Monotherapy: DREAM: Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (clinicaltrials.gov) - Dec 8, 2011
P2/3, N=420, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Selzentry (maraviroc) / ViiV Healthcare
Trial completion: A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients (clinicaltrials.gov) - Nov 22, 2011
P2, N=129, Completed, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial: Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression (clinicaltrials.gov) - Nov 14, 2011
P4, N=336, Recruiting, Sponsor: Juan A. Arnaiz
- lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: Ritonavir-boosted Lopinavir Monotherapy (clinicaltrials.gov) - Nov 9, 2011
P3, N=40, Completed, Sponsor: Bamrasnaradura Infectious Diseases Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
New P4 trial: RASSTER: RAltegravir Switch STudy: Effects on Endothelial Recovery (clinicaltrials.gov) - Oct 16, 2011
P4, N=24, Recruiting, Sponsor: UMC Utrecht
- ||| efavirenz / Generic mfg., lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: LYNX: A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine (clinicaltrials.gov) - Oct 12, 2011
P=N/A, N=346, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Completed
- | New P4 trial: A Study on Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Sep 27, 2011
P4, N=242, Completed, Sponsor: G
- tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination: Kaletra and Viread in Antiretroviral Na (clinicaltrials.gov) - Sep 18, 2011
P4, N=6, Terminated, Sponsor: Oklahoma State University Center for Health Sciences
Recruiting --> Completed Recruiting --> Terminated; Lack of enrollment